By Christiana Sciaudone
Investing.com -- Moderna (NASDAQ:MRNA) Inc. is up 2.6% after dropping 5% following a report that its Covid-19 vaccine will likely be going into advanced phase three clinical trials by the end of this month, Reuters reported.
The phase 3 clinical trial had reportedly been delayed because Moderna was changing the protocol of the research, The Motley Fool reported.
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said Thursday he hopes that there will be a vaccine ready by the end of 2020 or early 2021.
Shares have more than tripled in 2020.
Moderna is among five companies developing coronavirus vaccines that will testify before a sub-committee of the U.S. House Of Representatives later this month, Reuters reported.